EP1945218A2 - Utilisation d'activateurs de la cyclase de guanylate destinee a traiter des maladies pulmonaires aigues et chroniques - Google Patents

Utilisation d'activateurs de la cyclase de guanylate destinee a traiter des maladies pulmonaires aigues et chroniques

Info

Publication number
EP1945218A2
EP1945218A2 EP06777198A EP06777198A EP1945218A2 EP 1945218 A2 EP1945218 A2 EP 1945218A2 EP 06777198 A EP06777198 A EP 06777198A EP 06777198 A EP06777198 A EP 06777198A EP 1945218 A2 EP1945218 A2 EP 1945218A2
Authority
EP
European Patent Office
Prior art keywords
acute
treatment
lung diseases
compounds
pulmonary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06777198A
Other languages
German (de)
English (en)
Inventor
Thomas Krahn
Johannes-Peter Stasch
Gerrit Weimann
Wolfgang Thielemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of EP1945218A2 publication Critical patent/EP1945218A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to the use of compounds of the formulas I-VI for the manufacture of a medicament for the treatment of acute and chronic lung diseases such as the respiratory distress syndrome (acute acute respiratory distress syndrome (ARDS)) and the treatment of COPD ,
  • ARDS acute acute respiratory distress syndrome
  • COPD COPD
  • noxae directly harmful to the lungs may cause ALI or ARDS, respectively.
  • an acute lung disease associated with bilateral infiltrates in chest x-ray and severely impaired respiration after exposure to one of the above-mentioned noxae at a ratio of PaCvFiO 2 ⁇ 300 is said to be ALI, at a ratio of PaO 2 : FiO 2 ⁇ 200 from an ARDS.
  • the associated mortality is given as more than 50% and thus represents a serious intensive medical illness.
  • Pathophysiological findings include diffuse alveolar damage with invasion of neutrophils, macrophages, erythrocytes, hyaline membrane formation, leakage of high-protein edema fluid, and interruption of the alveolar epithelial barrier with pathologically increased permeability. Histologically, after the stage of pulmonary edema formation, there is an acute and chronic inflammatory reaction with a possible transition to fibrosis. Clinically, a drastically deteriorated gas exchange with reduced oxygenation and difficult ventilation through a disturbed ventilation-perfusion distribution. Most ALI / ARDS patients also have moderate pulmonary hypertension with increased pulmonary resistance, which is due to hypoxic vasoconstriction, destruction and obstruction of the pulmonary alveolar endothelium. In some ALI / ARDS patients, this can lead to right heart failure.
  • cGMP cyclic guanosine monophosphate
  • NO nitric oxide
  • GTP guanosine triphosphate
  • the soluble guanylate cyclases consist of two subunits and most likely contain heme per heterodimer, which is part of the regulatory center. This is central to the activation mechanism. NO can bind to the iron atom of the heme and thus significantly increase the activity of the enzyme. Heme-free preparations, on the other hand, can not be stimulated by NO. CO is also able to attack the iron central atom of the heme, whereby the stimulation by CO is much better than that by NO.
  • guanylate cyclase plays a crucial role in different physiological processes
  • the activators of soluble guanylate cyclase according to the invention are particularly suitable for the preparation of pharmaceutical substances / medicaments for lowering pulmonary hypertension.
  • the compounds of the formula I have to VI Regarding Improved Pharmacodynamic Properties 1
  • they exert pressure-lowering effects in the pulmonary-arterial circulation independently of the endogenous NO produced in the pulmonary circulation.
  • the stimulators of soluble guanylate cyclase enhance the effect of the endogenously produced NO and improve gas turnover through selective pulmonary vascular dilation of the ventilated areas, resulting in a reduction of the intrapulmonary shunt with an increase in oxygenation.
  • Cigarette smoke causes COPD as exogenous noxa
  • Genetic factors such as ⁇ Xi-antitrypsin deficiency or bronchial hyperreactivity play a minor role
  • Chronic bronchitis, fibrosing bronchiolitis and the Emphysema are the three pathological features of COPD, which contribute to a progressive and accelerated loss of forced endospasm vitality (FeVi)
  • cough and sputum are present for at least 3 months per year for at least two consecutive years.
  • dyspnoea occurs, first under stress, later also at rest.
  • Pulmonary vascular remodeling in COPD with fntimahyperplasia and medial hypertrophy is associated with chronic hypoxia, nicotine inflammatory stimuli and frequent bacterial exacerbations as well as hyperextension and airways obstruction.
  • moderate pulmonary arte- nal pressures greater than 40 mmHg are not uncommon in patients with at least one episode of acute respiratory failure
  • inhalative glucocorticoids are used to reduce the frequency of exacerbations and antibiotics in bacterial bronchitis or pneumonia to reduce the so-called dynamic hypnosis Disease can not be significantly influenced by any of the established therapeutic principles.
  • Long-term oxygen therapy is recommended if P A O 2 falls below 55 mmHg in respiratory global failure. Consistently applied, this therapy improves the prognosis, but it can not influence the remodeling of all layers of the pulmonary artery walls.
  • the soluble guanylate cyclase activators according to the invention are particularly suitable for the production of pharmaceutical substances / medicaments for the reduction of pulmonary hypertension.
  • the compounds of the formulas I to VI according to the invention have improved pharmacodynamic properties on the one hand irrespective of the endogenously produced in the pulmonary circulation NO even in severe endothelial damage and advanced disease pressure lowering in the pulmonary-artellen circulation addition strengthen the stimulators of the soluble guanylate cyclase the effect of the endogenously produced NO and thereby improve the gas exchange by a selective pulmonary vascular dilatation of the ventilated areas, which leads to a reduction of the intrapulmonary shunt with an increase in the oxy- gen.
  • the present invention is the use of compounds of formulas (I-VI) and their salts, hydrates, hydrates of the salts for the preparation of a medicament for the reduction of pulmonary hypertension.
  • Another object of the present invention is the use of compounds of formulas (I-VI) and their salts, hydrates, hydrates of the salts for the manufacture of a medicament for the treatment of acute and chronic lung diseases such as the Respiratory Distress Syndrome [acute lung Injury (ALI ), acute respiratory distress syndrome (ARDS)] and the treatment of COPD.
  • ALI acute lung Injury
  • ARDS acute respiratory distress syndrome
  • An additional embodiment of the present invention comprises the procedure for the prophylaxis and / or reduction of pulmonary hypertension using at least one of the compounds of the formulas (I-VI)
  • Another object of the present invention smd drugs containing at least one compound of the invention and at least one or more other active ingredients, in particular for the treatment and / or prophylaxis of the aforementioned diseases.
  • the compounds according to the invention can have a systemic and / or local action.
  • they can be administered in a suitable manner, such as, for example, orally, parenterally, pulmonarily, sal, sublingual, lingual, buccal, rectal, dermal, transdermal (topical), conjunctivae otic or as an implant or stent.
  • the compounds according to the invention can be administered in suitable administration forms.
  • Parenteral administration can be accomplished by bypassing a resorption step (e.g., intravenously, intraarterially, intracardially, intraspinal, or intralumbar) or by resorting to absorption (e.g., intramuscularly, subcutaneously, intracutaneously, percutaneously, or intraperitoneally).
  • a resorption step e.g., intravenously, intraarterially, intracardially, intraspinal, or intralumbar
  • absorption e.g., intramuscularly, subcutaneously, intracutaneously, percutaneously, or intraperitoneally.
  • parenteral administration are suitable as application forms u.a. Injection and infusion preparations in the form of solutions, suspensions, emulsions, lyophilisates or sterile powders.
  • Inhalation medicaments including powder inhalers, nebulizers
  • nasal drops solutions or sprays
  • lingual, sublingual or buccal tablets films / wafers or capsules
  • suppositories ear or ophthalmic preparations
  • vaginal capsules aqueous suspensions (lotions, shake mixtures)
  • lipophilic suspensions ointments
  • creams transdermal therapeutic systems (such as patches)
  • milk pastes, foams, scattering powders, implants or stents.
  • excipients include, but are not limited to, excipients (eg, microcrystalline cellulose, lactose, mannitol), solvents (eg, liquid polyethylene glycols), emulsifiers and dispersing or wetting agents (e.g., sodium dodecyl sulfate, polyoxysorbitanoleate), binders (e.g., polyvinylpyrrolidone), synthetic and natural polymers (e.g.
  • excipients eg, microcrystalline cellulose, lactose, mannitol
  • solvents eg, liquid polyethylene glycols
  • emulsifiers and dispersing or wetting agents e.g., sodium dodecyl sulfate, polyoxysorbitanoleate
  • binders e.g., polyvinylpyrrolidone
  • synthetic and natural polymers e.g.
  • Another object of the present invention are pharmaceutical compositions containing at least one compound of the formula (I-VI) according to the invention, usually together with one or more inert, non-toxic, pharmaceutically suitable excipients, and their use for the purposes mentioned above.
  • the formulations may contain from 0.1% to 99% active ingredient according to the procedure, suitably 25-95% for tablets and capsules and 1-50% for liquid formulations, ie the active ingredient should be present in sufficient amounts. to achieve the specified dosage margin.
  • mice were treated for 10 days with 300 ppm of Compound (IV) in the feed. At the end of the experiment, the mice were sacrificed and the lungs isolated. The histological processing and evaluation were carried out as in the above-mentioned publication. Compared with the hypoxia control animals, the non-muscularized and partially-muscularized fraction of the pulmonary vessels is significantly reduced in the mice treated with compound (IV) (FIG. 1).

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne l'utilisation de composés de formules I à VI destinés dans la production d'un médicament destiné à traiter des maladies pulmonaires aiguës et chroniques, telles que le syndrome de détresse respiratoire (ALI), le syndrome de détresse respiratoire aigu (SDRA), ainsi qu'à traiter la maladie pulmonaire obstructive chronique (MPOC).
EP06777198A 2005-10-06 2006-09-23 Utilisation d'activateurs de la cyclase de guanylate destinee a traiter des maladies pulmonaires aigues et chroniques Withdrawn EP1945218A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005047946A DE102005047946A1 (de) 2005-10-06 2005-10-06 Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von akuten und chronischen Lungenkrankheiten
PCT/EP2006/009264 WO2007039155A2 (fr) 2005-10-06 2006-09-23 Utilisation d'activateurs de la cyclase de guanylate destinee a traiter des maladies pulmonaires aigues et chroniques

Publications (1)

Publication Number Publication Date
EP1945218A2 true EP1945218A2 (fr) 2008-07-23

Family

ID=37106347

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06777198A Withdrawn EP1945218A2 (fr) 2005-10-06 2006-09-23 Utilisation d'activateurs de la cyclase de guanylate destinee a traiter des maladies pulmonaires aigues et chroniques

Country Status (13)

Country Link
US (1) US20090286781A1 (fr)
EP (1) EP1945218A2 (fr)
JP (1) JP2009510142A (fr)
KR (1) KR20080065283A (fr)
CN (1) CN101282727A (fr)
AU (1) AU2006299149A1 (fr)
BR (1) BRPI0616921A2 (fr)
CA (1) CA2624716A1 (fr)
DE (1) DE102005047946A1 (fr)
IL (1) IL190619A0 (fr)
RU (1) RU2417083C2 (fr)
WO (1) WO2007039155A2 (fr)
ZA (1) ZA200802874B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202008014557U1 (de) 2008-10-27 2009-03-12 Eberhard-Karls-Universität Tübingen Universitätsklinikum Therapeutische Verwendung
CN102770133A (zh) * 2010-02-05 2012-11-07 拜耳知识产权有限责任公司 用于治疗囊性纤维化的单独和与PDE5抑制剂组合的sGC刺激剂或sGC激活剂
EP2687210A1 (fr) * 2010-06-25 2014-01-22 Bayer Intellectual Property GmbH Stimulateurs et activateurs de la guanylate cyclase soluble pour leur utilisation dans le traitement de la drépanocytose et de la conservation des substituts sanguins
CN102485724B (zh) * 2010-12-06 2015-08-12 中国人民解放军军事医学科学院毒物药物研究所 取代噻吩基吡唑并吡啶类化合物及其医药用途
JP6005134B2 (ja) * 2011-04-21 2016-10-12 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ フルオロアルキル置換ピラゾロピリジンおよびその使用
RS55651B1 (sr) * 2012-07-20 2017-06-30 Bayer Pharma AG Nove 5-aminotetrahidrohinolin-2-karbonske kiseline i njihova upotreba
EP3024455A1 (fr) 2013-07-25 2016-06-01 Bayer Pharma Aktiengesellschaft Stimulateurs de sgc ou activateurs de sgc et inhibiteurs de pde5 en combinaison avec un autre traitement pour la thérapie de la fibrose kystique
CN108785309A (zh) * 2018-04-23 2018-11-13 周静 化合物在制备治疗慢性肺病的药物中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69529101T2 (de) * 1994-06-15 2003-11-13 Wellcome Found Zwischenprodukte verwendbar in der Herstellung von Enzym-Inhibitoren
DE19834044A1 (de) * 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943635A1 (de) * 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) * 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
EP1501605A1 (fr) * 2002-04-26 2005-02-02 ALTANA Pharma AG Nouvelle utilisation d'activateurs de la guanylate cyclase pour le traitement d'insuffisance respiratoire
DE10220570A1 (de) * 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
GB2395431A (en) * 2002-11-20 2004-05-26 Northwick Park Inst For Medica Combination of a metal carbonyl compound and a guanylate cyclase stimulant or stabilizer for the therapeutic delivery of carbon monoxide
AU2004262976A1 (en) * 2003-08-04 2005-02-17 Hemocorm Limited Use of boranocarbonates for the therapeutic delivery of carbon monoxide
JP2007505142A (ja) * 2003-09-10 2007-03-08 セダーズ−シナイ メディカル センター 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
GB0325291D0 (en) * 2003-10-29 2003-12-03 Pfizer Ltd Novel combination
DE10351903A1 (de) * 2003-11-06 2005-06-09 Bayer Healthcare Ag Neue Kombination
WO2005077005A2 (fr) * 2004-02-04 2005-08-25 The General Hospital Corporation Amelioration de l'efficacite d'un gaz therapeutique inhale
US20080138444A1 (en) * 2004-10-05 2008-06-12 Bayer Healthcare Ag Method For Treating Bronchoconstriction and Pulmonary Vaso-Constriction

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007039155A2 *

Also Published As

Publication number Publication date
RU2008117303A (ru) 2009-11-20
RU2417083C2 (ru) 2011-04-27
WO2007039155A3 (fr) 2007-10-11
CN101282727A (zh) 2008-10-08
IL190619A0 (en) 2008-12-29
CA2624716A1 (fr) 2007-04-12
ZA200802874B (en) 2009-09-30
US20090286781A1 (en) 2009-11-19
DE102005047946A1 (de) 2007-05-03
AU2006299149A1 (en) 2007-04-12
BRPI0616921A2 (pt) 2011-07-05
JP2009510142A (ja) 2009-03-12
KR20080065283A (ko) 2008-07-11
WO2007039155A2 (fr) 2007-04-12

Similar Documents

Publication Publication Date Title
DE60026855T2 (de) Synergistische kombination von roflumilast und salmeterol
DE69834955T2 (de) Neue Verwendung von Budesonide und Formoterol
DE69329381T2 (de) Anti-ischaemisches arzneimittel
EP2269647A2 (fr) Compositions médicamenteuses à base de composés à action anticholinergiques et de betamimétiques
EP0038438B1 (fr) Composants pharmaceutiques constitués de 1,2,5 oxadiazol-2-oxydes substitués pour utilisation comme médicaments et médicaments les contenant
EP1945218A2 (fr) Utilisation d'activateurs de la cyclase de guanylate destinee a traiter des maladies pulmonaires aigues et chroniques
EP0277352B1 (fr) Association synergétique d'azélastine et de théophylline ou d'azélastine et de bêta-mimétiques
DE69419954T2 (de) Arzneimittel zur Behandlung von Hauterkrankungen
EP1917008A2 (fr) Utilisation d'activateurs de la guanylate cyclase soluble pour traiter les phenomenes de raynaud
WO2007113170A1 (fr) Utilisation de strobilurine pour le traitement de troubles du metabolisme du fer
EP2004149B1 (fr) Compositions pharmaceutiques contenant du léflunomide
DE60311702T2 (de) Behandlung von Flavivirusinfizierungen
DE69316621T2 (de) Antivitale zusammensetzungen
EP1275638B1 (fr) Thérapie combineé pour le traitement des maladies immunologiques
DE69913145T2 (de) Substituierte beta-diketone und ihre anwendung
DE3407509A1 (de) Neue arzneimittelkombination zur behandlung von bluthochdruck und thromboembolischen erkrankungen
DE69904051T2 (de) Zubereitung enthaltend derivate von phenylaminothiophenessigsäure zur behandlung der akuten respiratorischen insuffizienz (ards) und der akuten respiratorischen insuffizienz bei kindern (irds)
KR20170005539A (ko) 디피리다몰을 유효 성분으로 함유하는 신장 질환 치료용 의약 조성물
DE3887426T2 (de) Eperisone als Hypotonikum.
DE2532180C2 (de) Verwendung von Etozolin bei der Bekämpfung der Hypertonie
DE3901508C2 (de) Arzneimittel auf der Grundlage eines Wismut enthaltenden Präparats in fester Form
DE10310908A1 (de) Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von pulmonaler Hypertonie
EP1519730A1 (fr) Nouvelle utilisation d'imidazotriazinones
WO2010055081A1 (fr) Utilisation d'inhibiteurs des leucotriènes pour le traitement des affections pulmonaires d'enfants prématurés
DE2162590A1 (de) Bronchialerweiterndes Mittel

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080506

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20080901

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER SCHERING PHARMA AG

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER INTELLECTUAL PROPERTY GMBH

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130625